UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): April 9, 2021

 

 

 

ANNOVIS BIO, INC.

 

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-39202   26-2540421

(State or Other Jurisdiction

of Incorporation) 

 

(Commission

File Number) 

 

(I.R.S. Employer

Identification No.) 

 

1055 Westlakes Drive, Suite 300
Berwyn, PA 19312

(Address of Principal Executive Offices, and Zip Code)

 

(610) 727-3913

Registrant’s Telephone Number, Including Area Code

 

Not Applicable

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common Stock, par value $0.0001
per share 		ANVS NYSE American

 

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

Item 5.02 Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On April 9, 2021, Reid S. McCarthy was appointed to the Board of Directors (the “Board”) of Annovis Bio, Inc. (the “Company”) and to the position of chairman of the Audit Committee of the Board. Mr. McCarthy is an independent director for general and audit committee purposes under applicable SEC rules and under the NYSE American LLC Company Guide. Mr. McCarthy also qualifies as an audit committee financial expert under applicable SEC rules. Mr. McCarthy, 67, is experienced in corporate financial management, operating management, and new venture development.

 

A specialist in bank, bond, and equity financings, Mr. McCarthy retired after serving from 2016 to 2019 as the Chief Financial Officer of JJ Haines & Company, Inc., a $400 million revenue distribution company operating internationally. Between 2011 and 2016, Mr. McCarthy provided consulting Chief Financial Officer services to several life sciences companies. Prior to his service as a consulting Chief Financial Officer, Mr. McCarthy served as Chief Financial Officer of Topaz Pharmaceuticals, Inc. from 2007 to 2011, in which capacity, among other things, Mr. McCarthy arranged over $34 million in capital investment to fund the development and FDA approval of Topaz Pharmaceuticals, Inc.’s therapeutic product. Mr. McCarthy and his colleagues successfully sold the company in late 2011 to Sanofi Pasteur, an international pharmaceuticals company. From 1993 to 2007 Mr. McCarthy served as a founding executive of several venture capital-backed companies operating in the senior real estate, bio-metric technology, and agribusiness industries, all of which were successfully sold. Mr. McCarthy's past positions include Vice President of Financing for Trinity Capital Corporation, Director-Project Financing for ASEA Brown Boveri, Inc., and officer positions with New York-based money center banks, including J.P. Morgan Chase. Mr. McCarthy holds an undergraduate degree in international relations from the University of New Hampshire and an MBA in international finance from New York University.

 

A press release announcing Mr. McCarthy’s appointment to the Board is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

 

 

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.   Description
99.1   Annovis Bio, Inc. press release dated April 15, 2021

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ANNOVIS BIO, INC.
     
Date: April 15, 2021 By: /s/ Jeffrey McGroarty  
    Name: Jeffrey McGroarty
    Title: Chief Financial Officer

 

 

 

 

 Exhibit 99.1

 

Annovis Bio Appoints Reid McCarthy to Board and
to Role of Audit Committee Chairman

 

BERWYN, PA. – April 15, 2021 – Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced the appointment of Reid S. McCarthy to its Board of Directors and to the role of Audit Committee chairman, effective April 9, 2021.

 

A specialist in bank, bond, and equity financings, McCarthy retired after serving from 2016 to 2019 as CFO of JJ Haines & Company, Inc., a $400 million revenue distribution company operating internationally. Previously, McCarthy provided CFO consulting services to several life sciences companies, served as CFO of Topaz Pharmaceuticals from 2007 to 2011, and served as a founding executive of several VC-backed companies operating in the senior real estate, biometric technology, and agri-business industries, all of which were successfully sold, from 1993 to 2007. McCarthy’s past positions include Vice President of Financing for Trinity Capital Corporation, Director-Project Financing for ASEA Brown Boveri, Inc., and officer positions with New York-based money center banks, including J.P. Morgan Chase. McCarthy holds an undergraduate degree in international relations from the University of New Hampshire and an MBA in international finance from New York University.

 

“We are delighted to welcome Reid to our board and audit committee,” commented Maria Maccecchini, Ph.D., CEO of Annovis Bio. “Annovis is entering an exciting period of corporate development as we near the completion of our two ongoing Phase 2a trials. Based on positive initial interim data announced last month, we believe we will ultimately move into pivotal trials, and having someone of Reid’s caliber on our board at this stage further strengthens the Company.”

 

“I am excited to work with the Annovis team as they execute on their mission of addressing chronic and acute neurodegeneration through a novel approach that offers new hope in the fight against the largest unmet need of our aging population,” said McCarthy.

 

About Annovis Bio

Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have two ongoing Phase 2a studies: one in AD patients and one in both AD and PD patients. For more information on Annovis, please visit the company’s website: www.annovisbio.com.

 

 

 

 

Forward-Looking Statements

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words, and include, without limitation, statements regarding the timing, effectiveness, and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including that clinical trials may be delayed and that the initial interim data referenced herein is interim data, conclusions as to which may be superseded by subsequent data we expect to receive in connection with Phase 2a trials and/or subsequent clinical trials. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

 

 

Investor Relations:

 

Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
Dave@redchip.com

  

SOURCE: Annovis Bio, Inc.